RIENNA FULMER: Open Payments
NPI 1245428879 · LANCASTER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,325 in 122 payments from 27 companies in 2025. Trend: 2023 $124 · 2024 $776 · 2025 $2,325
Food & beverage: $2,325
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $401 |
| EMD Serono, Inc. | 13 | $207 |
| Merz Pharmaceuticals, LLC | 18 | $197 |
| Abbott Laboratories | 4 | $165 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| Boston Scientific Corporation | 6 | $113 |
| Lundbeck LLC | 5 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $96 |
| SK Life Science, Inc. | 4 | $93 |
| TG Therapeutics, Inc. | 3 | $83 |
Products named: QULIPTA, Xeomin, ZEPOSIA, PROCLAIM, UBRELVY, VYEPTI, HYQVIA, BRIUMVI.
Industry payments across PA — which companies pay providers there.
